Life sciences · Journal article
Synthetic and Systems Biotechnology · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
In response to the global threat posed by multidrug-resistant Klebsiella pneumoniae, this study established an efficient heterologous expression system for the antimicrobial peptide N6 in Pichia pastoris X-33. By employing an innovative 6His-2Flag dual-tag fusion strategy coupled with formic acid-mediated cleavage, we achieved a high-yield production of N6, with a final titer of 1.02 g/L-significantly surpassing previous reports and meeting the threshold for scalable industrial production. The expressed N6 exhibited potent and broad-spectrum antibacterial activity against clinical isolates of K. pneumoniae, with MIC values ranging from 2 to 8 μg/mL. Mechanistic studies revealed that N6 exerted rapid bactericidal and biofilm-eradicating effects through a multimodal action involving membrane disruption, metabolic interference, and induction of oxidative stress. In a murine systemic infection model, the N6 treatment significantly improved survival rates of mice to 70% and reduced bacterial burdens in key organs. This work not only identifies N6 as a promising therapeutic candidate against drug-resistant bacterial infections, but also provides a streamlined and cost-effective synthetic biology platform for the high-level production of antimicrobial peptides, thereby facilitating their clinical translation and industrial application.